High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients

Transplant International

Volumn 23, Issue 5, 2010, Pages 465-475

  Rotondi, Mario ^a,b   Netti, Giuseppe Stefano ^a,c   Lazzeri, Elena ^a   Stallone, Giovanni ^c   Bertoni, Elisabetta ^d   Chiovato, Luca ^b   Grandaliano, Giuseppe ^e   Gesualdo, Loreto ^c   Salvadori, Maurizio ^d   Schena, Francesco Paolo ^e   Romagnani, Paola ^a   Serio, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF BARI   (Italy)

Author keywords

Acute rejection; Chemokine receptor CXCR3; CXCL9; Renal allograft survival; Renal graft loss; Renal graft outcome

Indexed keywords

CXCL9 CHEMOKINE; THYMOCYTE ANTIBODY; CXCL9 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CELL INFILTRATION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; AGED; BLOOD; CHEMISTRY; GENE EXPRESSION REGULATION; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; PREOPERATIVE PERIOD; RISK;

AGED; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CHEMOKINE CXCL9; FEMALE; GENE EXPRESSION REGULATION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; RISK; TREATMENT OUTCOME;

EID: 77950667962     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.01006.x     Document Type: Article

References (50)

1. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation - how much of the promise has been realized? Nat Med 2005 11 : 605.
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4 : 378.
3. Afzali B, Taylor AL, Goldsmith DJ. What we CAN do about chronic allograft nephropathy: role of immunosuppressive modulations. Kidney Int 2005 68 : 2429.
4. Roos-van Groningen MC, Scholten EM, Lelieveld PM, et al. Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. J Am Soc Nephrol 2006 17 : 881.
5. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002 73 : 1923.
6. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001 16 : 1545.
7. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999 341 : 1725.
8. Radermacher J, Mengel M, Ellis S, et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003 349 : 115.
9. Süsal C, Pelzl S, Döhler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002 13 : 1650.
10. Rotondi M, Rosati A, Buonamano A, et al. High pre-transplant serum levels of CXCL10/IP-10 are related to increased risk of renal allograft failure. Am J Transplant 2004 4 : 1466.
11. Lazzeri E, Rotondi M, Mazzinghi B, et al. High CXCL10 expression in rejected kidneys and predictive role of pre-transplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005 79 : 1215.
12. Rotondi M, Netti GS, Rosati A, et al. Pre-transplant serum FT3 levels in kidney graft recipients are useful for identifying patients with higher risk for graft failure. Clin Endocrinol 2008 68 : 220.
13. Hauser IA, Spiegler S, Kiss E, et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-gamma (MIG). J Am Soc Nephrol 2005 16 : 1849.
14. Menke J, Zeller GC, Kikawada E, et al. CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. J Am Soc Nephrol 2008 19 : 1177.
15. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713.
16. Romagnani P, Lazzeri E, Lasagni L, et al. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. J Am Soc Nephrol 2002 13 : 53.
17. Ponticelli C. Renal transplantation 2004: where do we stand today? Nephrol Dial Transplant 2004 19 : 2937.
18. Lewis MP, Norman JT. Differential response of activated versus nonactivated renal fibroblasts to tubular epithelial cells: A model of initiation and progression of fibrosis? Exp Nephrol 1998 6 : 132.
19. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I: Paracrine cells important in health and disease. Am J Physiol 1999 277 : C183.
20. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005 16 : 3755.
21. Romagnani S. Regulation of the T cell response. Clin Exp Allergy 2006 36 : 1357.
22. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev 2007 28 : 492.
23. Romagnani P, Annunziato F, Lasagni L, et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001 107 : 53.
24. Lasagni L, Francalanci M, Annunziato F, et al. An alternatively spliced variant of CXCR3 mediates the IP-10, Mig and I-TAC induced-inhibition of endothelial cell growth and acts as functional receptor for PF-4. J Exp Med 2003 197 : 1537.
25. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004 25 : 201.
26. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006 354 : 610.
27. Hancock WW, Lu B, Gao W, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000 192 : 1515.
28. el-Sawy T, Fahmy NM, Fairchild RL. Chemokines: directing leukocyte infiltration into allografts. Curr Opin Immunol 2002 14 : 562.
29. Romagnani P, Annunziato F, Lazzeri E, et al. Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) alphabeta+ CD8 + single-positive T cells, TCRgammadelta+ T cells, and natural killer-type cells in human thymus. Blood 2001 97 : 601.
30. Romagnani P, Beltrame C, Annunziato F, et al. Role for interactions between IP-10/Mig and their receptor (CXCR3) in proliferative glomerulonephritis. J Am Soc Nephrol 1999 10 : 2518.
31. Bonacchi A, Romagnani P, Romanelli RG, et al. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001 276 : 9945.
32. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine-receptors and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000 11 : 152.
33. Akalin E, Dikman S, Murphy B, Bromberg JS, Hancock WW. Glomerular infiltration by CXCR3 + ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 2003 3 : 1116.
34. Miura M, Morita K, Koyanagi T, Fairchild RL. Neutralization of monokine induced by interferon-gamma during the early posttransplantation period prevents development of chronic allograft vasculopathy and graft fibrosis. Transplant Proc 2003 35 : 875.
35. Zhang Z, Kaptanoglu L, Haddad W, et al. Donor T cell activation initiates small bowel allograft rejection through an IFN-γ-inducible protein-10-dependent mechanism. J Immunol 2002 168 : 3205.
36. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001 193 : 975.
37. Miura M, Morita K, Kobayashi H, et al. Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 2001 167 : 3494.
38. Hancock WW, Wang L, Ye Q, Han R, Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003 15 : 479.
39. Matz M, Beyer J, Wunsch D, et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short-and long-term graft function. Kidney Int 2006 69 : 1683.
40. Haskova Z, Izawa A, Contreras AG, Flynn E, Briscoe DM. Organ-specific differences in the function of MCP-1 and CXCR3 during cardiac and skin allograft rejection. Transplantation 2007 83 : 1595.
41. Kwun J, Hu H, Schadde E, et al. Altered distribution of H60 minor H antigen-specific CD8 T cells and attenuated chronic vasculopathy in minor histocompatibility antigen mismatched heart transplantation in Cxcr3-/- mouse recipients. J Immunol 2007 179 : 8016.
42. Kwun J, Hazinedaroglu SM, Schadde E, et al. Unaltered graft survival and intragraft lymphocytes infiltration in the cardiac allograft of Cxcr3-/- mouse recipients. Am J Transplant 2008 8 : 1593.
43. Zerwes H-G, Li J, Kovarik J, et al. The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats. Am J Transplant 2008 8 : 1604.
44. Fulkerson PC, Zimmermann N, Brandt EB, et al. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-[gamma] (Mig, CXCL9). Proc Natl Acad Sci USA 2004 101 : 1987.
45. Xanthou G, Duchesnes CE, Williams TJ, Pease JE. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur J Immunol 2003 33 : 2241.
46. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003 63 : 2803.
47. Koga S, Auerbach MB, Engeman TM, et al. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. J Immunol 1999 163 : 4878.
48. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and receptorgene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation 2003 75 : 20044.
49. Rosenblum JM, Zhang QW, Siu G, et al. CXCR3 antagonism impairs the development of donor-reactive, IFN-gamma-producing effectors and prolongs allograft survival. Transplantation 2009 87 : 360.
50. Auerbach MB, Shimoda N, Amano H, et al. Monokine induced by interferon-gamma (MIG/CXCL9) is derived from both donor and recipient sources during rejection of class II major histocompatibility complex disparate skin allografts. Am J Pathol 2009 174 : 2172.